How could new treatment options improve outcomes in FLT3-mutated AML?

During the 2022 ASCO Annual Meeting, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment options improve outcomes in FLT3-mutated acute myeloid leukemia (AML)?

Daver begins by outlining the nature of FLT3 mutations in patients with AML, including their association with a higher-risk prognosis, before discussing first- and second-generation FLT3 inhibitors and the studies that explored these. Daver goes on to outline a study on a venetoclax + gilteritinib combination in relapsed/refractory FLT3-mutated AML and its promising efficacy. Finally, Daver discusses studies aiming to improve outcomes for different patient groups, utilizing varying dosages and therapeutic combinations.